Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 31838007

Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Lancet Oncol
Publication date
2020 Feb
First author
Doebele RC

This record carries publication-notice metadata. Review the notices below before relying on it.

Publication notices

absence is not clearance
true
has correction metadata
true
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Oncol. 2020 Feb;21(2):193-194. doi: 10.1016/S1470-2045(19)30789-2.
    note
    Source null
    related pmid
    31838008
    relationship
    Comment in
  2. citation
    Lancet Oncol. 2020 Feb;21(2):e70. doi: 10.1016/S1470-2045(20)30029-2.
    note
    Source null
    related pmid
    32007204
    relationship
    Erratum in
  3. citation
    Lancet Oncol. 2020 Jul;21(7):e341. doi: 10.1016/S1470-2045(20)30345-4.
    note
    Source null
    related pmid
    32615115
    relationship
    Erratum in
  4. citation
    Lancet Oncol. 2020 Aug;21(8):e372. doi: 10.1016/S1470-2045(20)30382-X.
    note
    Source null
    related pmid
    32758469
    relationship
    Erratum in
  5. citation
    Lancet Oncol. 2021 Oct;22(10):e428. doi: 10.1016/S1470-2045(21)00538-6.
    note
    Source null
    related pmid
    34592190
    relationship
    Erratum in

Authors and identifiers

  1. name
    Doebele RC
    type
    Author
  2. name
    Drilon A
    type
    Author
  3. name
    Paz-Ares L
    type
    Author
  4. name
    Siena S
    type
    Author
  5. name
    Shaw AT
    type
    Author
  6. name
    Farago AF
    type
    Author
  7. name
    Blakely CM
    type
    Author
  8. name
    Seto T
    type
    Author
  9. name
    Cho BC
    type
    Author
  10. name
    Tosi D
    type
    Author
  11. name
    Besse B
    type
    Author
  12. name
    Chawla SP
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Doebele RC
    type
    Author
  2. name
    Drilon A
    type
    Author
  3. name
    Paz-Ares L
    type
    Author
  4. name
    Siena S
    type
    Author
  5. name
    Shaw AT
    type
    Author
  6. name
    Farago AF
    type
    Author
  7. name
    Blakely CM
    type
    Author
  8. name
    Seto T
    type
    Author
  9. name
    Cho BC
    type
    Author
  10. name
    Tosi D
    type
    Author
  11. name
    Besse B
    type
    Author
  12. name
    Chawla SP
    type
    Author
bibliography ids
  1. nci-bib-82957f58c3878dd39f2e24f4
book metadata
content sha256
2ac965586a0a77562feeaced15e6dd9f0d22fea1a2325edfcb7acca67a20c5f6
document type
citation
dois
  1. 10.1016/S1470-2045(19)30691-6
electronic publication date
display
2019 Dec 11
precision
day
year
2019
evidence scope
bibliographic_metadata_only
id
pubmed:31838007
immutable id
pubmed:31838007@2ac965586a0a77562feeaced15e6dd9f0d22fea1a2325edfcb7acca67a20c5f6
journal
abbreviation
Lancet Oncol
issn electronic
1474-5488
issn print
1470-2045
issue
2
name
The Lancet. Oncology
nlm unique id
100957246
pages
271-282
volume
21
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
true
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Oncol. 2020 Feb;21(2):193-194. doi: 10.1016/S1470-2045(19)30789-2.
    note
    Source null
    related pmid
    31838008
    relationship
    Comment in
  2. citation
    Lancet Oncol. 2020 Feb;21(2):e70. doi: 10.1016/S1470-2045(20)30029-2.
    note
    Source null
    related pmid
    32007204
    relationship
    Erratum in
  3. citation
    Lancet Oncol. 2020 Jul;21(7):e341. doi: 10.1016/S1470-2045(20)30345-4.
    note
    Source null
    related pmid
    32615115
    relationship
    Erratum in
  4. citation
    Lancet Oncol. 2020 Aug;21(8):e372. doi: 10.1016/S1470-2045(20)30382-X.
    note
    Source null
    related pmid
    32758469
    relationship
    Erratum in
  5. citation
    Lancet Oncol. 2021 Oct;22(10):e428. doi: 10.1016/S1470-2045(21)00538-6.
    note
    Source null
    related pmid
    34592190
    relationship
    Erratum in
outcomes validated
false
pmid
31838007
provenance
batch id
4c5003fbb78890e89ae1
provider
NCBI PubMed ESummary
record sha256
22563fd6c7100985fc3c441b791f6f2d843dcfdb242eba337cfa7a4514f563c6
response sha256
890389583ce193a9c74e19c63678e418dad2088e82cb704b888b02fcc887d269
retrieved at
2026-09-09T23:47:48.270700+00:00
publication date
display
2020 Feb
precision
month
year
2020
publication types
  1. Journal Article
  2. Research Support, Non-U.S. Gov't
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/31838007/
title
Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials.

Preserved source evidence · Not medical advice